BCAL Diagnostics Limited (AU:BDX)
ASX:BDX
Want to see AU:BDX full AI Analyst Report?
BDX Stock Chart & Stats
AU$0.10
>-AU$0.01(-2.06%)
At close: 4:00 PM EST
AU$0.10
>-AU$0.01(-2.06%)
Day’s Range― - ―
52-Week RangeAU$0.05 - AU$0.16
Previous CloseN/A
Volume98.04K
Average Volume (3M)421.90K
Market Cap
AU$28.39M
Enterprise ValueAU$29.94M
Total Cash (Recent Filing)AU$3.33M
Total Debt (Recent Filing)AU$3.78M
Price to Earnings (P/E)―
Beta0.65
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding368,683,300
10 Day Avg. Volume534,308
30 Day Avg. Volume421,904
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)3.64
Price to Sales (P/S)1047.06
P/FCF Ratio-3.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Manageable Leverage And Equity BufferA debt-to-equity of 0.38 and a 62.77% equity ratio indicate moderate leverage and a meaningful equity cushion. For a development-stage diagnostics business, this reduces near-term insolvency risk and provides balance sheet flexibility to fund R&D and regulatory steps over the next several months without immediate refinancing pressure.
Proprietary, Focused Business ModelBCAL operates a lab diagnostics service built on proprietary blood-based cancer detection technology and a clear initial focus on breast cancer. This product-led, service-delivery model supports recurring test volumes, potential clinical adoption alongside care pathways, and defensibility from IP and specialized lab processes over the medium term.
Some Free Cash Flow Coverage Versus Net LossesA free cash flow to net income ratio above 1 indicates pockets of cash conversion despite reported losses. This suggests the company can sometimes convert operations or related activities into cash, slightly extending runway and allowing management to prioritize commercialization activities or clinical validation over an immediate equity raise.
Bears Say
Sharp Revenue CollapseA near-total revenue collapse undermines commercial traction and market validation. Losing almost all revenue dramatically reduces ability to invest in sales, clinical studies, and regulatory work, increases reliance on external funding, and impairs the firm’s capacity to scale tests or retain clinical partnerships over months.
Severe And Persistent LossesExtremely negative margins demonstrate structural unprofitability and operational inefficiencies. Sustained deep losses will necessitate capital raises or cost restructuring, dilute shareholders, and constrain long-term investment in product development and commercialization necessary for diagnostic adoption.
Negative Operating Cash Flow And Cash Generation DeclineNegative operating cash flow and declining free cash flow growth indicate ongoing cash burn. That limits the company's runway for trials, regulatory submissions, and commercial rollout without additional financing, increasing execution risk and the probability of disruptive fundraising in the medium term.
BCAL Diagnostics Limited News
BDX FAQ
What was BCAL Diagnostics Limited’s price range in the past 12 months?
BCAL Diagnostics Limited lowest share price was AU$0.05 and its highest was AU$0.15 in the past 12 months.
What is BCAL Diagnostics Limited’s market cap?
BCAL Diagnostics Limited’s market cap is AU$28.39M.
When is BCAL Diagnostics Limited’s upcoming earnings report date?
BCAL Diagnostics Limited’s upcoming earnings report date is Sep 01, 2026 which is in 103 days.
How were BCAL Diagnostics Limited’s earnings last quarter?
BCAL Diagnostics Limited released its earnings results on Feb 17, 2026. The company reported -AU$0.011 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.011.
Is BCAL Diagnostics Limited overvalued?
According to Wall Street analysts BCAL Diagnostics Limited’s price is currently Overvalued.
Does BCAL Diagnostics Limited pay dividends?
BCAL Diagnostics Limited does not currently pay dividends.
What is BCAL Diagnostics Limited’s EPS estimate?
BCAL Diagnostics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BCAL Diagnostics Limited have?
BCAL Diagnostics Limited has 368,683,300 shares outstanding.
What happened to BCAL Diagnostics Limited’s price movement after its last earnings report?
BCAL Diagnostics Limited reported an EPS of -AU$0.011 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.348%.
Which hedge fund is a major shareholder of BCAL Diagnostics Limited?
Currently, no hedge funds are holding shares in AU:BDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BCAL Diagnostics Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Neutral
AU:BDX Sentiment 50%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$83.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.16%
12-Months-Change
Fundamentals
Return on Equity
-164.22%
Trailing 12-Months
Asset Growth
-37.01%
Trailing 12-Months
Company Description
BCAL Diagnostics Limited
BCAL Diagnostics Limited, a biotechnology company, engages in developing a non-invasive laboratory blood test for the detection of breast cancer. It develops BCAL test, a lipid biomarker blood test with the potential to be used for breast cancer prevention, screening, and monitoring; and in vitro diagnostic test (IVD) that confirms a fingerprint of lipid biomarkers extracted from extracellular vesicles from a patient's plasma or blood sample to diagnose the presence of breast cancer cells in a patient's body. The company was incorporated in 2010 and is headquartered in Sydney, Australia.
Technical Analysis
Rhythm Biosciences Ltd.
―
Lumos Diagnostics Holdings Ltd.
―
―
Imagion Biosystems Ltd.
―
Inoviq Ltd
―
Options Prices
Currently, No data available
---